TJ286B - A method for treatment or prevention of obesity - Google Patents

A method for treatment or prevention of obesity

Info

Publication number
TJ286B
TJ286B TJ96000313A TJ96000313A TJ286B TJ 286 B TJ286 B TJ 286B TJ 96000313 A TJ96000313 A TJ 96000313A TJ 96000313 A TJ96000313 A TJ 96000313A TJ 286 B TJ286 B TJ 286B
Authority
TJ
Tajikistan
Prior art keywords
obesity
growth hormone
effective amount
prevention
treatment
Prior art date
Application number
TJ96000313A
Inventor
Ross G Clark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of TJ286B publication Critical patent/TJ286B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method is disclosed for treating obese mammals or preventing obesity from occurring in mammals. This method involves administering to the mammal an effective amount of growth hormone in combination with an effective amount of IGF-1. Preferably, the growth hormone is given so as to have a maintained, continual therapeutically effective presence in the blood, such as by continuous infusion or frequent injections, or by use of a long-acting formulation.
TJ96000313A 1992-10-29 1993-10-26 A method for treatment or prevention of obesity TJ286B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96862392A 1992-10-29 1992-10-29
PCT/US1993/010259 WO1994009813A1 (en) 1992-10-29 1993-10-26 Method for treatment or prevention of obesity

Publications (1)

Publication Number Publication Date
TJ286B true TJ286B (en) 2000-12-13

Family

ID=25514516

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000313A TJ286B (en) 1992-10-29 1993-10-26 A method for treatment or prevention of obesity

Country Status (13)

Country Link
EP (1) EP0669832B1 (en)
JP (1) JPH08502969A (en)
AT (1) ATE143267T1 (en)
AU (1) AU675996B2 (en)
CA (1) CA2145501C (en)
DE (1) DE69305091T2 (en)
DK (1) DK0669832T3 (en)
ES (1) ES2095086T3 (en)
GR (1) GR3022074T3 (en)
LV (1) LV11987B (en)
MD (1) MD1486G2 (en)
TJ (1) TJ286B (en)
WO (1) WO1994009813A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TW318226B (en) * 1995-05-11 1997-10-21 Sega Enterprises Kk
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
CA2345642A1 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
SE0000837D0 (en) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
DE10035227A1 (en) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
JP5108303B2 (en) 2003-08-21 2012-12-26 テルシカ インコーポレーティッド Method for reducing visceral fat by increasing insulin-like growth factor (IGF-I) levels
RU2317118C1 (en) * 2006-09-21 2008-02-20 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Method for treating lipodystrophy in diabetes mellitus patients
US20240317832A1 (en) * 2021-07-29 2024-09-26 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate
WO2023004687A1 (en) * 2021-07-29 2023-02-02 浙江新码生物医药有限公司 Unnatural amino acid and application thereof, recombinant protein containing same, and recombinant protein conjugate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
JP3051145B2 (en) * 1990-08-28 2000-06-12 住友製薬株式会社 Novel polyethylene glycol derivative modified peptide
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Also Published As

Publication number Publication date
AU675996B2 (en) 1997-02-27
MD960245A (en) 1997-12-31
WO1994009813A1 (en) 1994-05-11
DE69305091T2 (en) 1997-03-13
EP0669832A1 (en) 1995-09-06
ATE143267T1 (en) 1996-10-15
ES2095086T3 (en) 1997-02-01
CA2145501A1 (en) 1994-05-11
LV11987B (en) 1998-06-20
GR3022074T3 (en) 1997-03-31
MD1486G2 (en) 2001-11-30
JPH08502969A (en) 1996-04-02
CA2145501C (en) 2004-08-10
MD1486F2 (en) 2000-06-30
EP0669832B1 (en) 1996-09-25
LV11987A (en) 1998-03-20
AU5451294A (en) 1994-05-24
DE69305091D1 (en) 1996-10-31
DK0669832T3 (en) 1997-03-17

Similar Documents

Publication Publication Date Title
DK0536226T3 (en)
AU7178287A (en) Remote administration of hyaluronic acid to mammals
GR3022074T3 (en) Method for treatment or prevention of obesity.
EP1077721B8 (en) Prevention and treatment of hypergastrinemia
KR920700227A (en) Super Highly Active Human Insulin Homolog
HU9500714D0 (en) Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
US7220413B2 (en) Pharmaceutical composition containing inhibitors of interferon-γ
Sassolas et al. Nocturnal continuous infusion of growth hormone (GH)-releasing hormone results in a dose-dependent accentuation of episodic GH secretion in normal men
GB1474424A (en) Pharmaceutical composition for treating diabetic ketoacidosis
GB2304342A (en) Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
EP0317933A3 (en) Treatment of fibromyalgia
GB2260702B (en) Improvements relating to the treatment of haemophilia B by subcutaneous injection of factor 1X
EP0486944A3 (en) Method of inhibiting tumor growth using xanthocillin x dimethylether
Habib Calcium and Hormone Therapy of Essential Hypertension
MX9709958A (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus.
EP1839673A3 (en) Prevention and treatment of hypergastrinemia
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
UA31148A (en) The method for treatment of psoriasis